Author

Prachi Ghodke

Institution: Syneos Health (India)

Observed institutions: Bristol-Myers Squibb (United States), Syneos Health (India)

OpenAlex ID: A5120636765

KarMMa-3 Subgroup Analysis in Older Patients with Relapsed/Refractory Multiple Myeloma Treated with Idecabtagene Vicleucel

2026 · Sikander Ailawadhi, Bertrand Arnulf, et al. · Transplantation and Cellular Therapy · 1

KarMMa-3 subgroup analysis in older patients with relapsed/refractory multiple myeloma treated with idecabtagene vicleucel

2025 · Sikander Ailawadhi, Bertrand Arnulf, et al. · Blood · 1

Efficacy and safety of lisocabtagene maraleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: 31-month follow-up of the phase 2 TRANSCEND FL study

2026 · Shinichi Makita, Hideki Goto, et al. · International Journal of Clinical Oncology

Clinical Outcomes of Lisocabtagene Maraleucel (liso-cel) in Younger Patients (Pts) with Relapsed or Refractory (R/R) Large B-cell Lymphoma (LBCL)

2026 · Irtiza N. Sheikh, Krish Patel, et al. · Transplantation and Cellular Therapy

Works count: 4

Citation count: 2

H-index: 1

I10-index: